

International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,¹ notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in the *WHO Chronicle*, e.g., for List 51 Prop. INN not later than 31 August 1984.

The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.


Proposed International Nonproprietary Names (Prop. INN): List 51²

Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number

acidum acetohydroxamicum
acetohydroxamic acid

acetohydroxamic acid
C₂H₃NO₂ 546-88-3



Comprehensive information on the INN programme can be found in: WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*, Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 (price: Sw. fr. 6.-), an account of this publication will be found on page 21 of this Supplement (Annex 2). All names from Lists 1-47 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in: *International Nonproprietary Names (INN) for Pharmaceutical Substances Cumulative List No. 6*, 1982, World Health Organization, Geneva (ISBN 92 4 056013 0) (price: Sw. fr. 55.-). This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to April 1982. The printout also indicates in which of the 47 individual lists of proposed names and 21 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, molecular formulae, and Chemical Abstracts Service registry numbers are indexed in a series of annexes. A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.

These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of the *WHO Chronicle*. Orders from countries where sales agents have not yet been appointed may be addressed to: World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.

¹ See Annex 1, p. 19


² Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 6*, 1982.

Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


acifranum
acifran

(±)-4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furoic acid
C₁₂H₁₀O₄ 72420-38-3




acrivastinum
acrivastine

(E)-6-[(E)-3-(1-pyrrolidiny)-1-p-tolylpropenyl]-2-pyridineacrylic acid
C₂₂H₂₄N₂O₂ 87848-99-5




ademetoninum
ademetonine

(S)-5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine
hydroxide, inner salt
C₁₅H₂₂N₆O₅S 29908-03-0




aganodinum
aganodine

(4,7-dichloro-2-isoindoliny)guanidine
C₈H₁₀Cl₂N₄ 86696-87-9



amifloxacinum
amifloxacin

6-fluoro-1,4-dihydro-1-(methylamino)-7-(4-methyl-1-piperaziny)-4-oxo-3-
quinolinecarboxylic acid
C₁₆H₁₉FN₄O₃ 86393-37-5




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


bioresmethrinum
bioresmethrin

(5-benzyl-3-furyl)methyl (+)-*trans*-2,2-dimethyl-3-(2-methylpropenyl)-
cyclopropanecarboxylate
C₂₂H₂₆O₃ 28434-01-7




biriperonum
biriperone

(±)-4'-fluoro-4-(3,4,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-
2(1*H*)-yl)butyrophenone
C₂₄H₂₆FN₃O 41510-23-0




bromerguridum
bromerguride

3-(2-bromo-9,10-didehydro-6-methylergolin-8α-yl)-1,1-diethylurea
C₂₆H₂₅BrN₄O 83455-48-5




broxaterolum
broxaterol

(±)-3-bromo-α-[(*tert*-butylamino)methyl]-5-isoxazolemethanol
C₉H₁₃BrN₂O₂ 76596-57-1



buparvaquonum
buparvaquone

2-[(4-*tert*-butylcyclohexyl)methyl]-3-hydroxy-1,4-naphthoquinone
C₂₇H₂₈O₃ 88426-33-9




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


butanserinum
butanserin

3-[4-[4-(*p*-fluorobenzoyl)piperidino]butyl]-2,4(1*H*,3*H*)quinazolinedione
C₂₄H₂₆FN₃O₃ 87051-46-5




carumonamum
carumonam

(*Z*)-[[[(2-amino-4-thiazolyl)[[(2*S*,3*S*)-2-(hydroxymethyl)-4-oxo-1-sulfo-3-azetidiny]carbonyl]methylene]amino]oxy]acetic acid, carbamate (ester)
C₁₂H₁₄N₆O₁₀S₂ 87638-04-8




cetirizinum
cetirizine

(±)-[2-[4-(*p*-chloro-*o*-phenylbenzyl)-1-piperazinyl]ethoxy]acetic acid
C₂₁H₂₅ClN₂O₃ 83881-51-0




cimetropii bromidum
cimetropium bromide

8-(cyclopropylmethyl)-6β,7β-epoxy-3α-hydroxy-1αH,5αH-tropanium bromide,
(-)-(*S*)-tropate
C₂₁H₂₄BrNO₄ 51598-60-8



ciprostenum
ciprostene

(*Z*)-(3*aS*,5*R*,6*R*,6*aR*)-hexahydro-5-hydroxy-6-[(*E*)-(3*S*)-3-hydroxy-1-octenyl]-3*a*-methyl-Δ^{2(1*H*),3}-pentalenevaleric acid
C₂₂H₃₆O₄ 81845-44-5




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number

climazolamum
climazolam

8-chloro-6-(o-chlorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
 $C_{18}H_{13}Cl_2N_3$ 59467-77-5




colistimethatum natricum
colistimethate sodium

an antibiotic obtained from colistin sulfate by sulfomethylation with
formaldehyde and sodium bisulfite
8068-28-8


dazmegrelum
dazmegrel

3-(imidazol-1-ylmethyl)-2-methylindole-1-propionic acid
 $C_{16}H_{17}N_3O_2$ 76894-77-4




deloxolonum
deloxolone

3β-hydroxyolean-9(11)-en-30-oic acid, hydrogen succinate
 $C_{34}H_{52}O_6$ 68635-50-7




dezaguaninum
dezaguanine

6-amino-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
 $C_6H_6N_4O$ 41729-52-6



dibrospidii chloridum
dibrospidium chloride

3,12-bis(3-bromopropionyl)-3,12-diaza-6,9-diazoniadispiro[5.2.5.2]hexadecane
dichloride
 $C_{18}H_{32}Br_2Cl_2N_4O_2$ 86641-76-1




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


diproteverinum
diproteverine

1-(3,4-diethoxybenzyl)-3,4-dihydro-6,7-diisopropoxyisoquinoline
 $C_{28}H_{35}NO_4$ 69373-95-1




divabuterolum
divabuterol

(±)-5-[2-(*tert*-butylamino)-1-hydroxyethyl]-*m*-phenylene dipivalate
 $C_{22}H_{39}NO_5$ 54592-27-7




dronabinolum
dronabinol

(6*aR*,10*aR*)-6*a*,7,8,10*a*-tetrahydro-6,6,9-trimethyl-3-pentyl-6*H*-
dibenzo[*b,d*]pyran-1-ol
 $C_{21}H_{30}O_2$ 1972-08-3




eb selenium
eb selen

2-phenyl-1,2-benzisoseleazol-3-one
 $C_{13}H_9NOSe$ 60940-34-3



eldexomerum
eldexomer

product of etherification of hydrolysed starch with epichlorhydrin in the
presence of excess alkali




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


epostanum
epostane

4 α ,5-epoxy-3,17 β -dihydroxy-4,17-dimethyl-5 α -androst-2-ene-2-carbonitrile
C₂₂H₃₁NO₃ 80471-63-2




etazepinum
etazepine

(\pm)-11-ethoxy-5,11-dihydro-5-methyl-6H-dibenz[b,e]azepin-6-one
C₁₇H₁₇NO₂ 88124-27-0




etretinum
etretin

(*all-E*)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
C₂₇H₂₆O₃ 55079-83-9




fenoldopamum
fenoldopam

6-chloro-2,3,4,5-tetrahydro-1-(*p*-hydroxyphenyl)-1H-3-benzazepine-7,8-diol
C₁₆H₁₆ClNO₃ 67227-56-9




fenretinidum
fenretinide

all-trans-4'-hydroxyretinanilide
C₂₆H₃₃NO₂ 65646-68-6



fepradinolum
fepradinol

(\pm)- α -[[(2-hydroxy-1,1-dimethylethyl)amino]methyl]benzyl alcohol
C₁₂H₁₉NO₂ 63075-47-8




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


flurithromycinum
flurithromycin

(8S)-8-fluoroerythromycin
 $C_{37}H_{66}FNO_{13}$ 82664-20-8




fostedilum
fostedil

diethyl (*p*-2-benzothiazolylbenzyl)phosphonate
 $C_{18}H_{20}NO_3PS$ 75889-62-2



frabuprofenum
frabuprofen

2-[4-(*a,a,a*-trifluoro-*m*-tolyl)-1-piperaziny]ethyl (\pm)-*p*-isobutylhydratropate
 $C_{28}H_{33}F_3N_2O_2$ 86696-88-0




glunicatum
glunicate

2-deoxy-2-nicotinamido- β -D-glucopyranose 1,3,4,6-tetranicotinate
 $C_{30}H_{28}N_6O_{10}$ 80763-86-6



imidazoli salicylas
imidazole salicylate

salicylic acid, compound with imidazole (1.1)
 $C_{10}H_{10}N_2O_3$ 36364-49-5




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


iofetaminum (¹²³I)
iofetamine (¹²³I)

(±)-*p*-iodo-¹²³I-N-isopropyl- α -methylphenethylamine
C₁₂H₁₆¹²³I N 75917-92-9




ipramidilum
ipramidil

N,N-diisopropyl-3,4-furazandicarboxamide 2-oxide
C₁₀H₁₆N₄O₄ 83656-38-6




iproplatinum
iproplatin

ab-dichloro-*ce*-dihydroxy-*df*-bis(isopropylamine)platinum
C₆H₂₀Cl₂N₂O₂Pt 62928-11-4




ketorolacum
ketorolac

(±)-5-benzoyl-2,3-dihydro-1*H*-pyrrolizine-1-carboxylic acid
C₁₃H₁₃NO₃ 74103-06-3



losulazinum
losulazine

1-[(*p*-fluorophenyl)sulfonyl]-4-[*p*-[[7-(trifluoromethyl)-4-quinolyl]amino]benzoyl]piperazine
C₂₇H₂₂F₄N₄O₃S 72141-57-2




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


lutrelinum
lutrelin

5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-N-methyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide
C₆₅H₉₃N₁₇O₁₂ 66866-63-5




mafosfamidum
mafosfamide

(±)-2-[2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl]thio]ethanesulfonic acid *P-cis*-oxide
C₈H₁₈Cl₂N₂O₃PS₂ 88859-04-5




mecetronii etilsulfas
mecetronium etilsulfate

ethylhexadecyldimethylammonium ethyl sulfate
C₂₂H₄₈NO₄S 3006-10-8




menogarilum
menogaril

(2*R**,3*S**,4*R**,5*R**,6*R**,11*R**,13*R**)-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2*H*-naphthaceno[1,2-*b*]oxocin-9,16-dione
C₂₈H₃₁NO₁₀ 71628-96-1



mespirenonum
mespirenone

15α,16α-dihydro-17-hydroxy-7α-mercapto-3-oxo-3'*H*-cyclopropa[15,16]-17α-pregna-1,4,15-triene-21-carboxylic acid, γ-lactone, acetate
C₂₅H₃₀O₄S 87952-98-5



Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


mipimazolium
mipimazole

1-isopropyl-2-imidazolidinethione
 $C_6H_{12}N_2S$ 20406-60-4




mitozolomidum
mitozolomide

3-(2-chloroethyl)-3,4-dihydro-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide
 $C_7H_7ClN_6O_2$ 85622-95-3




nocloprostum
nocloprost

(Z)-7-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E)-(3R)-3-hydroxy-4,4-dimethyl-1-octenyl]cyclopentyl]-5-heptenoic acid
 $C_{22}H_{37}ClO_4$ 79360-43-3




otimeratum natricum
otimerate sodium

ethyl(hydrogen 2-mercapto-5-benzoxazolecarboxylato)mercury, sodium salt
 $C_{10}H_8HgNNaO_3S$ 16509-11-8




artamidum
artamide

(±)-tetrahydro-N-methyl-2-(2-pyridyl)thio-2-thiophenecarboxamide
 $C_{17}H_{14}N_2S_2$ 76732-75-7



piriprostum
piriprost

(4R,5R)-1,4,5,6-tetrahydro-5-hydroxy-4-[(E)-(3S)-3-hydroxy-1-octenyl]-1-phenylcyclopenta[b]pyrrole-2-valeric acid
 $C_{28}H_{35}NO_4$ 79672-88-1




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


ramifenazonum
ramifenazone

4-(isopropylamino)-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one
C₁₄H₁₉N₃O 3615-24-5




revenastum
revenast

2,3-diphenyl-1-[3-[4-(2-pyridyl)-1-piperazinyl]propyl]-3-pyrazolin-5-one
C₂₇H₂₉N₅O 85673-87-6




ridazololum
ridazolol

(±)-4-chloro-5-[[2-[[[3-(o-chlorophenoxy)-2-hydroxypropyl]amino]ethyl]amino]-3(2H)-pyridazinone
C₁₉H₁₈Cl₂N₄O₃ 83395-21-5




riodipinum
riodipine

dimethyl 4-[o-(difluoromethoxy)phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
C₁₈H₁₉F₂NO₅ 71653-63-9



ristianolum
ristianol

2-[(4-pyridylmethyl)thio]ethanol
C₈H₁₁NOS 78092-65-6




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


ritanserinum
ritanserin

6-[2-[4-[bis(*p*-fluorophenyl)methylene]piperidino]ethyl]-7-methyl-5*H*-
thiazolo[3,2-*a*]pyrimidin-5-one
C₂₇H₂₅F₂N₃OS 87051-43-2




ronipamilum
ronipamil

(±)-2-[3-(methylphenethylamino)propyl]-2-phenyltetradecanenitrile
C₃₂H₄₈N₂ 85247-77-4




setoperonum
setoperone

6-[2-[4-(*p*-fluorobenzoyl)piperidino]ethyl]-2,3-dihydro-7-methyl-5*H*-
thiazolo[3,2-*a*]pyrimidin-5-one
C₂₁H₂₄FN₃O₂S 86487-64-1




somantadinum
somantadine

α,α-dimethyl-1-adamantaneethylamine
C₁₄H₂₅N 79594-24-4




taltibridum
taltibride

2-chloro-*N,N*-dimethyl-5-[3-methyl-2-(phenylimino)-4-thiazolin-4-
yl]benzenesulfonamide
C₁₈H₁₈ClN₃O₂S₂ 77989-60-7



tazasubratum
tazasubrate

(±)-α-[(6-ethoxy-2-benzothiazolyl)thio]hydratropic acid
C₁₈H₁₇NO₃S₂ 79071-15-1




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


tenilsetamum
tenilsetam

(±)-3-(2-thienyl)-2-piperazinone
C₉H₁₀N₂OS 86696-86-8




tetramethrinum
tetramethrin

2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylic acid, ester with *N*-(hydroxymethyl)-1-cyclohexene-1,2-dicarboximide or 1-cyclohexene-1,2-dicarboximidomethyl 2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylate
C₁₉H₂₅NO₄ 7696-12-0




tilsuprostum
tilsuprost

methyl (±)-4-[(3*aR**,4*R**,5*R**,6*aS**)-3,3*a*,4,5,6,6*a*-hexahydro-5-hydroxy-4-[(*E*)-(3*S**)-3-hydroxy-1-octenyl]cyclopenta[*b*]pyrrol-2-yl]thio]butyrate
C₂₀H₃₃NO₄S 80225-28-1




timobesonum
timobesone

S-methyl 9-fluoro-11β,17-dihydroxy-16β-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate
C₂₂H₂₅FO₄S 87116-72-1



tolrestatum
tolrestat

N-[6-methoxythio-5-(trifluoromethyl)-1-naphthoyl]sarcosine
C₁₄H₁₄F₃NO₃S 82964-04-3




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


tolufazepamum
tolufazepam

7-chloro-5-(*o*-chlorophenyl)-1,3-dihydro-1-[2-(*p*-tolylsulfonyl)ethyl]-2*H*-1,4-
benzodiazepin-2-one
 $C_{24}H_{20}Cl_2N_2O_3S$ 86273-92-9




transcainidum
transcainide

(±)-*trans*-4-(dimethylamino)-1-(2-hydroxycyclohexyl)-2',6'-isonipecoxyliidide
 $C_{22}H_{35}N_3O_2$ 88296-62-2




trazopridum
trazopride

N-(1-benzyl-4-piperidyl)-6-methoxy-1*H*-benzotriazole-5-carboxamide
 $C_{20}H_{23}N_5O_2$ 86365-92-6




valdetamidum
valdetamide

2,2-diethyl-4-pentenamide
 $C_9H_{17}NO$ 512-48-1




valproatum pivoxilum
valproate pivoxil

hydroxymethyl 2-propylvalerate, pivalate
 $C_{14}H_{24}O_4$ 77372-61-3



vincantrilum
vincantril

(±)-10-chloro-1,2,3,3a,4,5-hexahydro-6*H*-indolo[3,2,1-*de*][1,5]naphthyridin-
6-one
 $C_{14}H_{13}ClN_2O$ 65285-58-1




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number


vintriptolum
vintriptol

[23(S)]-4-deacetyl-3-[(1-carboxy-2-indol-3-ylethyl)carbamoyl]-3-de(methoxycarbonyl)vincalukoblastine, ethyl ester
 $C_{36}H_{48}N_4O_8$ 81600-06-8




zinci acetat basicum
zinc acetate, basic

hexakis(μ -acetato)- μ 4-oxotetrazinc
 $C_{22}H_{18}O_{13}Zn_4$ 82279-57-0



zofenoprilum
zofenopril

(4S)-N-[(S)-3-mercapto-2-methylpropionyl]-4-(phenylthio)-L-proline
benzoate (ester)
 $C_{22}H_{23}NO_4S_2$ 81872-10-8



**AMENDMENT
TO PREVIOUS LISTS**

Cumulative List No. 6, 1982

International Nonproprietary Names (INN) for Pharmaceutical Substances:

	<i>delete</i>	<i>insert</i>
p. 7	acidum halocrinicum halocrinic acid	brocrinatum brocrinat
	acidum indacrinicum indacrinic acid	indacrinonum indacrinone
p. 259	propranololum propranolol	<i>replace INN in Spanish by propranolol</i>
p. 265	quisultidinum quisultidine	quisultazinum quisultazine

Vol. 36, No. 2

International Nonproprietary Names (Prop. INN): List 47

	<i>delete</i>	<i>insert</i>
p. 9	iotrolum iotrol	iotrolanum iotrolan

Vol. 36, No. 5


International Nonproprietary Names (Prop. INN): List 48

	<i>delete</i>	<i>insert</i>
p. 11	iodecolum iodecol	iodecimolum iodecimol

Vol. 37, No. 2

International Nonproprietary Names (Prop. INN): List 49

p. 2	alifedrinum alifedrine	<i>replace the graphic formula by:</i>
------	---------------------------	--




	<i>delete</i>	<i>insert</i>
p. 4	boforsinum boforsin	colforsinum colforsin

p. 6 dazodipinum
dazodipine

darodipinum
darodipine


p. 13 nacartocinum
nacartocin

replace the graphic formula by:



p. 16 piroxicillinum
piroxicillin

replace the graphic formula by:



Annex 1
**PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL
NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES***

The following procedure shall be followed by the World Health Organization in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with the World Health Assembly resolution WHA3.11:

1. Proposals for recommended international nonproprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Nonproprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international nonproprietary name is being considered.

A. Such notice shall be given by publication in the *Chronicle of the World Health Organization*¹ and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

(i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

- (i) set forth the name under consideration;
- (ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;
- (iii) identify the substance for which a name is being considered;
- (iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;
- (v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.¹

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.¹

A. Such objection shall:

- (i) identify the person objecting;
- (ii) state his interest in the name;
- (iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international nonproprietary name.

8. In forwarding a recommended international nonproprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the nonproprietary name for the substance; and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

* Text adopted by the Executive Board of WHO in resolution EB15 R7 (*Off. Rec. World Health Org.*, 1955, 60, 3) and amended by the Board in resolution EB43 R9 (*Off. Rec. World Health Org.*, 1969, 173, 10).

¹ The title of this publication was changed to *WHO Chronicle* in January 1959.

**GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING
INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES**

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological,

pathological or therapeutic suggestion should be avoided.

These primary principles are to be implemented by using the following secondary principles

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. "oxacillin" and "oxacillin sodium", "ibufenac" and "ibufenac sodium".

5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ

only in respect of the name of the inactive acid or the inactive base.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7 To facilitate the translation and pronunciation of INN, "f" should be

used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y"; the use of the letters "h" and "k" should be avoided.

8 Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in INN (see Guiding Principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.¹ Where a stem is shown without any hyphens it may be used anywhere in the name.

<i>Latin</i>	<i>English</i>	
-acum	-ac	anti-inflammatory agents of the ibufenac group
-actidum	-actide	synthetic polypeptides with a corticotrophin-like action
-adolum	-adol	} analgesics
-adol-	-adol-	
-astum	-ast	} anti-asthmatic, anti-allergic substances not acting primarily as antihistaminics
-astinum	-astine	
-azepamum	-azepam	substances of the diazepam group
-bactamum	-bactam	β -lactamase inhibitors
bol	bol	steroids, anabolic
-buzonium	-buzone	anti-inflammatory analgesics of the phenylbutazone group
-cain-	-cain-	antifibrilliant substances with local anaesthetic activity
-cainum	-caine	local anaesthetics
cef-	cef-	antibiotics, derivatives of cephalosporanic acid
-cillinum	-cillin	antibiotics, derivatives of 6-aminopenicillanic acid
cort	cort	corticosteroids, except those of the prednisolone group
-dipinum	-dipine	peripheral vasodilators of the nifedipine group
-fibratum	-fibrate	substances of the clofibrate group
-forminum	-formin	hypoglycemics of the phenformin group
gest	gest	steroids, progestogens
gli-	gli-	sulfonamide hypoglycemics
io-	io-	iodine-containing contrast media
-ium	-ium	quaternary ammonium compounds
-metacinum	-metacin	anti-inflammatory substances of the indometacin group
-mycinum	-mycin	antibiotics, produced by <i>Streptomyces</i> strains
-nidazolium	-nidazole	antiprotozoal substances of the metronidazole group
-ololum	-olol	β -adrenergic blocking agents of the propranolol group
-oxacinum	-oxacin	antibacterial agents of the nalidix acid group
-pridum	-pride	sulpiride derivatives
-profenum	-profen	anti-inflammatory substances of the ibuprofen group
prost	prost	prostaglandins
-relinum	-relin	hypophyseal hormone release-stimulating peptides
-terolum	-terol	bronchodilators, phenethylamine derivatives
-tidinum	-tidine	H ₂ -receptor antagonists
-trexatum	-trexate	folic acid antagonists
-verinum	-verine	spasmolytics with a papaverine-like action
vin-	vin-	} vinca type alkaloids
-vin-	-vin-	

¹ A more extensive listing of stems is contained in the working document Pharm S/Nom 15 which is regularly updated and can be requested from Pharmaceuticals, WHO, Geneva

Annex 2

NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES: TWENTIETH REPORT OF THE WHO EXPERT COMMITTEE

In its twentieth report¹ the WHO Expert Committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, international nonproprietary names (INN) in the light of developments in pharmaceutical compounds in recent years. The most significant recent change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves employing a characteristic "em" indicative of a common property of the members of a group. The reasons for, and the implications of, the change are fully discussed. Also

reported is the intention to change the practice with regard to the nomenclature of individual members of polymeric series.

Other sections of the report concern instructions to be followed by bodies making application for international nonproprietary names, the availability of computer-printed cumulative lists of international nonproprietary names, information supplied by WHO Member States concerning their official use of national or international names for pharmaceutical products, and proposals relative to the withdrawal of international nonproprietary names allocated to substances that are no longer in use.

The official texts relating to the procedures for selecting, and general

guidance for devising, international nonproprietary names are reproduced in two annexes to the report. Other annexes give examples of international nonproprietary names that incorporate selected stems, the most frequently used initial groups of letters in international nonproprietary names, a historical review of the programme of selecting international nonproprietary names, some useful literature references, and a model of the form to be used in all applications for international nonproprietary names.

¹ WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*, Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 Price Sw. fr. 6.-